drugset / Trial / NCT00931138

Treatment of Acute Myeloid Leukemia (AML) in Adults 50 to 70 Years, Study of Two Anthracyclines and the Interest of Maintenance Treatment With Interleukin 2

NCT00931138

RandomizedParallel-groupOpen-labelTreatment

Summary

Randomized comparison of standard induction treatment with daunorubicin for 3 days and Idarubicin for 3 or 4 days in adult AML patients between 50 and 70 years. Study of maintenance treatment with IL2

Timeline

Start
1999-12
Primary completion
Completion
2006-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Daunorubicin Small molecule 80 mg/m2
Comparator Idarubicin Small molecule 12 mg/m2
Comparator Cytarabine Small molecule 200 mg/m2 Intravenous